Alpharma Inc. said the U.S. Food and Drug Administration approved a 200 mg dosage of Kadian, a chronic pain reliever capsule.
Alpharma expects to launch the capsule in the second quarter, the specialty pharmaceutical company said in a statement.
ALO is up 47 cents per share in late afternoon trading at $26.81/share in light trading (volume just under 482K0).
What is Kadian and how does it work?:
Kadian is sustained release morphine designed for 12-24 hour dosing. Cancer patients with chronic pain were randomized in clinical trials. Remember that morphine is an opiate which elicits its mechanism of action via specific receptors in the brain and GI tract. The major classes of opioid receptors are mu [for morphine], delta and kappa. These receptors are G protein coupled and each subtype can elicit varying effects. They effect intracellular signaling pathways such as calcium release, protein phosphorylation and ion gating.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment